Yeah, though the cash burn is a little less with t
Post# of 148185
(Total Views: 400)
Posted On: 08/15/2019 8:38:28 AM
Yeah, though the cash burn is a little less with that having some is stock and deprecation I'm not surprised. The added 200 mono patients have increased the burn rate.
With any fund raising, my guess is they will raise enough money to get through the BLA submission done next month.
One interesting item, most of the burn rate is going towards the mono trial. If they can do this, if the pivotal trial is approved, the burn rate is cut drastically.
With any fund raising, my guess is they will raise enough money to get through the BLA submission done next month.
One interesting item, most of the burn rate is going towards the mono trial. If they can do this, if the pivotal trial is approved, the burn rate is cut drastically.
Quote:
Upon finalization with the FDA of the pivotal trial protocol for monotherapy, this Phase2b/3 investigative trial will likely be discontinued.
(0)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼